India faces platinum cancer drug shortage
Analysis based on 11 articles · First reported Jun 09, 2026 · Last updated Jun 09, 2026
The shortage of platinum-based cancer drugs in India>>> directly impacts pharmaceutical companies like Cipla>>>, Intas Pharmaceuticals>>>, Naprod Life Sciences>>>, and Tridus Remedies>>> by increasing their raw material costs and potentially reducing production. The rising prices of Impala Platinum>>> as a commodity are a key driver, affecting the global supply chain and potentially leading to higher costs for other industries that rely on it.
India>>> is facing a severe shortage of platinum-based cancer drugs, including cisplatin and carboplatin, essential for treating various cancers. This crisis is primarily driven by a surge in global Impala Platinum>>> prices, constrained mine supply, and disruptions from conflicts in the Middle East>>> affecting imports from countries like South Africa>>>. The Indian>>> government's price caps on these medicines prevent drugmakers like Naprod Life Sciences>>> and Tridus Remedies>>> from passing on increased costs, leading some to halt production or absorb losses. Patients, exemplified by Kumar Ajit>>>, are struggling to find necessary dosages, putting immense pressure on the healthcare system. The All India Organisation of Chemists and Druggists>>> has confirmed the widespread supply crunch.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard